Matthew T David insider trades
Open-market stock purchases and sales by Matthew T David, Chief Financial Officer at Actinium Pharmaceuticals, Inc, from SEC Form 4 filings since May 11, 2020.
Track record: 100% of 4 scored buys are up 5% or more since purchase, averaging +80%.